Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paternally expressed 13 (PEG13) is a paternally imprinted long non-coding RNA (lncRNA) gene found in humans (chromosome 8) and mice (chromosome 15)[1][2][3]. It has a key regulatory role in the brain, including modulating neural differentiation, social and sexual behavior, and the expression of other imprinted genes and neuronal function genes[1]. PEG13 also modulates inflammation, notably by suppressing the proinflammatory cytokines HMGB1 and IL-6, and its expression is associated with a reduced inflammatory response in sepsis models, making it a potential therapeutic target for inflammatory diseases[2][4]. In humans, PEG13 is linked to Birk-Barel syndrome, a rare neurological disorder[3]. Loss or dysregulation of PEG13 leads to major behavioral changes, especially related to social interaction, sexual preference, and possibly anxiety and activity levels[1]. PEG13 acts by influencing gene networks rather than encoding a protein, and its exact molecular mechanisms remain under investigation[1][2][4].
As a non-coding RNA, PEG13 regulates gene expression, including imprinted genes and inflammation-related pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paternally expressed 13 (PEG13).